2 results
Approved WMOCompleted
Primary objective: To demonstrate that QVA149 (110/50 *g o.d.) is at least non-inferior to salmeterol/fluticasone (50/500 *g b.i.d.) in terms of rate of COPD exacerbations.Secondary objectives: Superiority in terms of exacerbation rate. Time to…
Approved WMOCompleted
- To determine the response based on Palmo-plantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at the end of treatment (week 24), or at the latest assessment for patients who withdraw prematurely